All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How can cytogenetics predict response to venetoclax and azacitidine in MDS?
How can cytogenetics predict response to venetoclax and azacitidine in MDS?
Venetoclax is an orally bioavailable BCL-2 inhibitor that has demonstrated promising efficacy in combination with azacitidine. Here, Jacqueline Garcia discusses the ongoing phase Ib clinical trial, M15531 (NCT02942290), evaluating the safety and efficacy of venetoclax + azacitidine in patients with treatment-naïve, higher-risk MDS, and subgroup analyses.
The real-world experience of venetoclax and hypomethylating agent therapy in high-risk myelodysplastic syndromes
The current standard of care for patients with high-risk myelodysplastic syndromes (MDS) is treatment with the hypomethylating agents...
Practice-changing abstracts at EHA 2020
The MDS Hub was pleased to speak to Steering Committee Chair Theo De Witte, Radboudumc, Nijmegen, NL, about practice-changing abstracts from the 25th European Hematology Association (EHA) Annual Congress.
Subscribe to get the best content related to MDS delivered to your inbox